Doravirine is a non-nucleoside reverse transcriptase inhibitor under development of Merck & Co. IC 50 value is 12 nM against the wild type, 21nM against K103N, 31 nM against Y181C, 33nM against K103N/Y181C mutant viruses in vitro. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses. Phase III for the treatment of HIV-1 infections is on-going.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | DNA/RNA Synthesis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye